EpCAM

Product List

Creative Biolabs has successfully developed a comprehensive range of EpCAM-related products to aid in global customers’ CAR-T development.

Background

Epithelial cell adhesion molecule (EpCAM) or CD326, is a kind of extensive epithelial differentiation antigen expressed in different degrees in the basolateral surface of all tumors. As a kind of homotypic cell adhesion molecule, which is closely related to the Cadherin-Catenin and WNT pathways, and participated in the cell adhesion process through Ca²⁺ independent homophilic cell-cell adhesion. EpCAM is involved in the cancer cell invasion and metastasis process, and is associated with poor prognosis in many cancer types. Anti-EpCAM CART development serves as a promising therapy approach for the treatment of many cancers, including colon cancer, breast cancer, etc.

Fig.1 Schematic diagram of EpCAM localization and regulation in the cancer pathway.¹

Associated Diseases

• Esophagus squamous cell carcinomas
• Renal cancer (RCC)
• Ovarian cancer
• Colorectal cancer
• Breast cancer

Anti-EpCAM CAR-T Services

Anti-EpCAM CAR-T In Vitro Assays

Anti-EpCAM CAR-T Expression Test

At Creative Biolabs, we supply a wide range of CAR testing reagents, including different labeled antigen-specific reagents, and different linker-specific antibodies. Meanwhile, we offer various approaches to support CART testing services, such as flow cytometry, qPCR, and WB methods.

Fig.2 Analysis of CD3ζ and EpCAM CAR expression on anti-EpCAM CART cells. B) CD3ζ expression measured by WB. C) EpCAM-CAR expression detected by flow cytometry.²

Anti-EpCAM CAR-T Cytokine Release Test

The cytokine-releasing capability of CART cells serves as an index for function characterization, providing some potential information for CART development. Creative Biolabs is committed to offering comprehensive cytokine testing services using methods that are more tailored to customer needs, including ELISA, ELISPOT, and Luminex-based multiple cytokine array.

Fig.3 Cytokine IFN-γ releasing analysis in anti-EpCAM CART cells co-cultured with SKOV-3 ovarian cancer cell line for 24hrs.²

Anti-EpCAM CAR-T In Vitro Cytotoxicity Assay

For in vitro anti-tumor testing, we provide various robust approaches to aid in customers' projects, including luminescence detection, fluorescence detection, and real-time cell analysis assay.

Fig.4 In vitro cytotoxicity evaluation of anti-EpCAM CART cells against SKOV3 target cells detected by RTCA assay.²

Anti-EpCAM CAR-T In Vivo Assays

Efficacy Test of Anti-EpCAM CAR-T

Regarding the invivo efficacy test, we offer a comprehensive range of animal models, as well as optimized experimental design solutions for CART development to suit various needs of global customers.

Fig.5 In vivo effects analysis of tumor growth and survival in intraparenchymal CAR T-cell injection model. k). Tumor growth detection of pooled tumor areas following local injection of GFP labeled anti-EpCAM CAR T-cells (green lane) or GFP labeled control T-cells (gray lane) on indicated timeline determined by in vivo microscopy using epifluorescence. I). Mice survival analysis with brain tumors following treatment with GFP labeled anti-EpCAM CAR T-cells (green lane) or GFP labeled control T-cells (gray lane).³

In Vivo CART Cells Characterization Analysis

In order to detect the relevant performance of CART cells in in vivo animal models, we have also developed a number of dynamic analysis services to accurately characterize the function of CART cells.

Fig.6 In vivo dynamic analysis of anti-EpCAM CAR-T distribution after intraparenchymal injection using epifluorescence (a&c) and two-photon laser scanning microscopy (b&d).³

Toxicity Evaluation Anti-EpCAM CAR-T

Therapeutic efficacy assessment and toxicity evaluation results are very important experimental data to evaluate whether the CART project can be continued in the CART development. Creative Biolabs is committed to providing robust and reliable toxicity evaluation services to accelerate CART projects, such as off-target toxicity analysis, and tumorigenicity study.

References

1. Mohtar, M. Aiman, et al. "Revisiting the roles of pro-metastatic EpCAM in cancer." Biomolecules 10.2 (2020): 255.
2. Fu, Juan, et al. "Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model." Journal of Veterinary Medical Science 83.2 (2021): 241-247.
3. Xu, Tao, et al. "In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer." OncoImmunology 12.1 (2023): 2163781.